alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 10.2

Diplomat Pharmacy, Inc. 
 Non-Employee Director Compensation Program

 

(effective April 4, 2017)

 

	
Annual cash retainer:
    	
 
    	
 
    	
 
    
	
Board
    	
 
    	
$
    	
75,000
    	
 
    
	
Additional   annual cash retainer:
    	
 
    	
 
    	
 
    
	
Lead Director
    	
 
    	
$
    	
30,000
    	
 
    
	
Audit   Committee-Chair
    	
 
    	
$
    	
15,000
    	
 
    
	
Compensation   Committee-Chair
    	
 
    	
$
    	
10,000
    	
 
    
	
Nominating and   Corporate Governance Committee-Chair
    	
 
    	
$
    	
10,000
    	
 
    
	
Annual   grant of restricted stock (grant date fair value):
    	
 
    	
 
    	
 
    
	
Board
    	
 
    	
$
    	
85,000
    	
 
    
	
Special   grant of restricted stock (grant date fair value):
    	
 
    	
 
    	
 
    
	
Lead Director
    	
 
    	
$
    	
75,000
    	
 
    


 

In addition, the Company reimburses expenses associated with attendance at Board meetings for all directors.

 

Restricted Stock - Board.  Each non-employee director will be paid the annual grant of restricted stock as of the earlier of (a) June 1 and (b) the date of the annual meeting of shareholders.  Notwithstanding the foregoing, the initial restricted stock grant for a new non-employee director appointed other than at the annual meeting of shareholders shall be made as of the date of initial appointment, having a pro rata grant date fair value as determined by the Board or the Compensation Committee.

 

The restricted stock vests in full on the first anniversary of the grant date or earlier upon a change of control of the Company, subject to the director’s continued service to the Company through such vesting date. Except as set forth in the prior sentence, the restricted stock will be forfeited in the event of termination of service prior to the vesting date.  During the restricted period, the restricted stock entitles the participant to all of the rights of a shareholder, including the right to vote the shares and the right to receive any dividends thereon. Prior to the end of the restricted period, restricted stock generally may not be sold, assigned, pledged, or otherwise disposed of or hypothecated by participants.

 

Restricted Stock — Lead Director.  In connection with Mr. Wolin’s appointment as the initial Lead Director of the Board, he received a grant of restricted stock.  The restricted stock vests 50% on the first anniversary of the initial appointment and 50% on the second anniversary (or earlier upon a change of control of the Company), subject to Mr. Wolin’s continued service to the Company as Lead Director through such vesting dates. Except as set forth in the prior sentence, the restricted stock will be forfeited in the event of termination of service as Lead Director prior to the vesting date.  During the restricted period, the restricted stock entitles Mr. Wolin to all of the rights of a shareholder, including the right to vote the shares and the right to receive any dividends thereon. Prior to the end of the restricted period, the restricted stock generally may not be sold, assigned, pledged, or otherwise disposed of or hypothecated.
§ 522.863 Ethylisobutrazine. ( a ) *Specifications.* Each milliliter of solution contains 50 milligrams (mg) of ethylisobutrazine hydrochloride.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer 2 to 5 mg per pound of body weight by intramuscular injection for profound tranquilization. Administer 1 to 2 mg per pound of body weight by intravenous injection to effect.
( 2 ) *Indications for use.* For use as a tranquilizer.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16187, Mar. 25, 2014]
<TABLE> <S> <C>


<ARTICLE>                     5
<CIK>                         0000814458
<NAME>                        HEALTHCARE PROPERTIES, L.P.
<MULTIPLIER>                                   1
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                              DEC-31-1997
<PERIOD-START>                                 JAN-01-1997
<PERIOD-END>                                   MAR-31-1997
<CASH>                                         9,231,206
<SECURITIES>                                   0
<RECEIVABLES>                                  5,173,468
<ALLOWANCES>                                   (4,240,811)
<INVENTORY>                                    0
<CURRENT-ASSETS>                               0
<PP&E>                                         36,176,401
<DEPRECIATION>                                 (14,375,492)
<TOTAL-ASSETS>                                 32,478,483
<CURRENT-LIABILITIES>                          0
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       0
<OTHER-SE>                                     24,413,445
<TOTAL-LIABILITY-AND-EQUITY>                   32,478,483
<SALES>                                        0
<TOTAL-REVENUES>                               2,382,121
<CGS>                                          0
<TOTAL-COSTS>                                  1,833,849
<OTHER-EXPENSES>                               26,851
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             172,601
<INCOME-PRETAX>                                348,820
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            0
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   348,820
<EPS-PRIMARY>                                  0
<EPS-DILUTED>                                  0
        


</TABLE>
§ 582.5915 Tryptophane. ( a ) *Product.* Tryptophane (L- and DL-forms).
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 522.230 Buprenorphine. ( a ) *Specifications.* Each milliliter of solution contains 1.8 milligrams (mg) buprenorphine.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in cats* — ( 1 ) *Amount.* Administer 0.24 mg per kilogram (0.11 mg per pound) by subcutaneous injection once daily, for up to 3 days. Administer the first dose approximately 1 hour prior to surgery.
( 2 ) *Indications for use.* For the control of postoperative pain associated with surgical procedures in cats.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 53136, Sept. 8, 2014, as amended at 80 FR 18776, Apr. 8, 2015]
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr., Chief Justice

Michael F. Cavanagh

Stephen J. Markman

Mary Beth Kelly

Brian K. Zahra

Bridget M. McCormack, Justices

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

 _________________________________________

 Clerk

February 6, 2013

s0130

Order 

February 6, 2013

146238

PEOPLE OF THE STATE OF MICHIGAN,

Plaintiff-Appellant,

v SC: 146238

COA: 305107

Wayne CC: 11-002420-FH

JAMES MICHAEL GEIERMAN,

Defendant-Appellee.

_________________________________________/

On order of the Court, the application for leave to appeal the September 18, 2012 

judgment of the Court of Appeals is considered and, pursuant to MCR 7.302(H)(1), in 

lieu of granting leave to appeal, we REVERSE, in part, the judgment of the Court of 

Appeals and REINSTATE the defendant’s conviction for felonious assault because the 

evidence was sufficient to sustain his conviction for that offense. The defendant broke 

into a home, threatened to strike the occupants with what appeared to be a small bat or 

club, and thus attempted “to commit a battery or [committed] an unlawful act that 

place[d] another in reasonable apprehension of receiving an immediate battery.” People 

v Nickens, 470 Mich 622, 628 (2004) (quotation marks and citations omitted). The Court 

of Appeals is required to view the evidence in a light most favorable to the prosecution. 

It was not empowered to substitute its judgment for that of the circuit court. People v 

Wolfe, 440 Mich 508, 515-516 (1992).
§ 522.2092 Secobarbital and dibucaine. ( a ) *Specifications.* Each milliliter (mL) of solution contains 400 milligram (mg) secobarbital sodium and 25 mg dibucaine hydrochloride.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Special considerations.* Product labeling shall bear the following warning statements: “ENVIRONMENTAL HAZARD: This product is toxic to wildlife. Birds and mammals feeding on treated animals may be killed. Euthanized animals must be properly disposed of by deep burial, incineration, or other method in compliance with State and local laws, to prevent consumption of carcass material by scavenging wildlife.”
( d ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer 1 mL per 10 pounds of body weight as a single, bolus intravenous injection.
( 2 ) *Indications for use.* For humane, painless, and rapid euthanasia.
( 3 ) *Limitations.* Do not use in animals intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[85 FR 18120, Apr. 1, 2020]
Exhibit 32.2



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Annual Report of Ambassadors International, Inc. (the Company) on Form 10-K for the year ended December 31, 2004 as filed with the
Securities and Exchange Commission on the date hereof (the Report), the undersigned, Brian R. Schaefgen, Chief Financial Officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
| | --- | -------------------------------------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|                                                                                  
|----------------------------------------------------------------------------------
|                                                                                  
|/s/    BRIAN R.
SCHAEFGENBrian R.
Schaefgen Chief Financial Officer March 16, 2005
|
|
|



The foregoing
certification is being furnished solely to accompany this Report pursuant to 18 U.S.C. §1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into
any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > National Labor Relations Act

              														National Labor Relations Act, July 5, 1935.						https://fraser.stlouisfed.org/title/5568,			accessed on September 21, 2024.						    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
----

| Dated:                   February 19, 2008 |   |
|------------------------------------------------------|--------|
|                                                 |   |
| /s/                  John W. Low                     |   |
| John                  W. Low                         |   |
|                                                 |   |
| Chief                  Financial Officer             |   |

----
§ 7.41 Health hazard evaluation and recall classification. ( a ) An evaluation of the health hazard presented by a product being recalled or considered for recall will be conducted by an ad hoc committee of Food and Drug Administration scientists and will take into account, but need not be limited to, the following factors: ( 1 ) Whether any disease or injuries have already occurred from the use of the product.
( 2 ) Whether any existing conditions could contribute to a clinical situation that could expose humans or animals to a health hazard. Any conclusion shall be supported as completely as possible by scientific documentation and/or statements that the conclusion is the opinion of the individual(s) making the health hazard determination.
( 3 ) Assessment of hazard to various segments of the population, e.g., children, surgical patients, pets, livestock, etc., who are expected to be exposed to the product being considered, with particular attention paid to the hazard to those individuals who may be at greatest risk.
( 4 ) Assessment of the degree of seriousness of the health hazard to which the populations at risk would be exposed.
( 5 ) Assessment of the likelihood of occurrence of the hazard.
( 6 ) Assessment of the consequences (immediate or long-range) of occurrence of the hazard.
( b ) On the basis of this determination, the Food and Drug Administration will assign the recall a classification, i.e., Class I, Class II, or Class III, to indicate the relative degree of health hazard of the product being recalled or considered for recall.
Final Listing of Questionnaire Files for Steam Electric Rulemaking Record

Plant ID 00693

Removed 

from Public 

(Non-CBI) 

Docket1

Copyright 

Flag2

File Name Description

00693\00693_ HardcopyLog.doc EPA log of hardcopy documents submitted

x 00693\00693_Checklist.XLS EPA Technical Review Checklist Workbook

00693\00693_Completeness_Checklist.xls EPA Completeness Review Checklist

x 00693\00693_PART A.XLS Plant submitted survey file

x 00693\00693_PART B.XLS Plant submitted survey file

x 00693\00693_PART C.XLS Plant submitted survey file

x 00693\00693_PART D.XLS Plant submitted survey file

x 00693\00693_PART H.XLS Plant submitted survey file

00693\SUPPORTING DOCUMENTS\00693_ MAP-1.pdf Plant submitted supplemental files to the survey

x 00693\SUPPORTING DOCUMENTS\00693_ OHH Diagram D-1.pdf Plant submitted supplemental files to the survey

x 00693\SUPPORTING DOCUMENTS\00693_ OHH Diagram D-2.pdf Plant submitted supplemental files to the survey

x 00693\SUPPORTING DOCUMENTS\00693_ OHH Diagram D-3.pdf Plant submitted supplemental files to the survey

x 00693\SUPPORTING DOCUMENTS\00693_ OHH Diagram WB-1.pdf Plant submitted supplemental files to the survey

00693\SUPPORTING DOCUMENTS\00693_ OHH Diagram WB-2.pdf Plant submitted supplemental files to the survey

x 00693\SUPPORTING DOCUMENTS\00693_ OHH Diagram WWT-1.pdf Plant submitted supplemental files to the survey

1

 Final reviewed survey responses are located in the Steam Electric Technical Questionnaire Database . 

2

 Copyright documents are available from the docket.
#### State of Connecticut *v.*Jacob Schafer

*John P. McKeon,*in support of the petition.

*Dennis F. Gaffney,*assistant chief prosecuting attorney, in opposition.

Submitted July 7

decided September 24, 1969

The petition by the defendant for certification for appeal from the Appellate Division of the Circuit Court is denied.
<TABLE> <S> <C>
                               
<ARTICLE>                                   5
<LEGEND>                         
     This schedule  contains summary  financial  information  extracted from the
Partnership's  unaudited financial statements for the quarter ended December 31,
1998 and is qualified in its entirety by reference to such financial statements.
</LEGEND>                        
<MULTIPLIER>                            1,000
                                     
<S>                                       <C>
<PERIOD-TYPE>                           9-MOS
<FISCAL-YEAR-END>                 Mar-31-1999
<PERIOD-END>                      Dec-31-1998
<CASH>                                  6,494
<SECURITIES>                                0
<RECEIVABLES>                              57
<ALLOWANCES>                                0
<INVENTORY>                                 0
<CURRENT-ASSETS>                        6,551
<PP&E>                                 17,598
<DEPRECIATION>                          2,688
<TOTAL-ASSETS>                         21,468
<CURRENT-LIABILITIES>                  11,312
<BONDS>                                     0
<PREFERRED-MANDATORY>                       0
<PREFERRED>                                 0
<COMMON>                                    0
<OTHER-SE>                             10,156
<TOTAL-LIABILITY-AND-EQUITY>           21,468
<SALES>                                     0
<TOTAL-REVENUES>                        5,439
<CGS>                                       0
<TOTAL-COSTS>                           1,187
<OTHER-EXPENSES>                            0
<LOSS-PROVISION>                            0
<INTEREST-EXPENSE>                      1,374
<INCOME-PRETAX>                         2,878
<INCOME-TAX>                                0
<INCOME-CONTINUING>                     2,878
<DISCONTINUED>                              0
<EXTRAORDINARY>                             0
<CHANGES>                                   0
<NET-INCOME>                            2,878
<EPS-PRIMARY>                           56.43
<EPS-DILUTED>                           56.43
        

</TABLE>
# C_2015346EN.01002801.xml

| 19.10.2015 | EN | Official Journal of the European Union | C 346/28 |
| --- | --- | --- | --- |

19.10.2015

EN

Official Journal of the European Union

C 346/28

---

Judgment of the General Court of 9 September 2015 — Dairek Attoumi v OHIM — Diesel (DIESEL)

(Case T-278/14) (1)

1

((Community design - Invalidity proceedings - Registered Community design DIESEL - Earlier international word mark DIESEL - Ground for invalidity - Use of a distinctive sign - Likelihood of confusion - Article 25(1)(e) of Regulation (EC) No 6/2002 - Proof of genuine use - Stay of the administrative proceedings))

(2015/C 346/32)

Language of the case: Spanish

Parties

Parties

Applicant: Mansour Dairek Attoumi (Badalona, Spain) (represented by: E. Manresa Medina and J. Manresa Medina, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: O. Mondéjar Ortuño and V. Melgar, Agents)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM, intervening before the General Court: Diesel SpA (Breganze, Italy) (represented by: F. Celluprica and F. Fischetti, lawyers)

Other party to the proceedings before the Board of Appeal of OHIM, intervening before the General Court:

Re:

Re:

Action brought against the decision of the Third Board of Appeal of OHIM of 18 February 2014 (Case R 855/2012-3), relating to invalidity proceedings between Diesel SpA and Mansour Dairek Attoumi.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Mansour Dairek Attoumi to pay the costs. |
| --- | --- |

2.

Orders Mansour Dairek Attoumi to pay the costs.

---

(1)  OJ C 253, 4.8.2014.

1

---
# C_2015034EN.01001801.xml

| 2.2.2015 | EN | Official Journal of the European Union | C 34/18 |
| --- | --- | --- | --- |

2.2.2015

EN

Official Journal of the European Union

C 34/18

---

Appeal brought on 9 December 2014 by Jean-Charles Marchiani against the judgment of the General Court (Third Chamber) delivered on 10 October 2014 in Case T-479/13 Marchiani v Parliament

(Case C-566/14 P)

(2015/C 034/20)

Language of the case: French

Parties

Parties

Appellant: Jean-Charles Marchiani (represented by: C.-S. Marchiani, avocat)

Appellant:

Other party to the proceedings: European Parliament

Other party to the proceedings:

Form of order sought

Form of order sought

| — | Set aside the judgment of the General Court (Third Chamber) of 10 October 2014 in Case T-479/13 Jean-Charles Marchiani v European Parliament. |
| --- | --- |

—

Set aside the judgment of the General Court (Third Chamber) of 10 October 2014 in Case T-479/13 Jean-Charles Marchiani v European Parliament.

Pleas and main arguments

Pleas and main arguments

In support of his appeal, the appellant raises five grounds of appeal.

Firstly, he believes that the General Court erred in law in refusing to apply to him the texts implementing the Statute for Members of the European Parliament. The decision of 4 July 2013 was taken following proceedings which were irregular since they ran counter to the decision of the European Parliament Bureau of 19 May and 9 July 2008 implementing the Statute for Members of the European Parliament. In addition, that decision was adopted, more generally, in breach of the adversarial principle and the principle of respect for the rights of the defence.

Secondly, the General Court erred in law and vitiated its reasoning by a contradiction in the grounds by referring to the PEAM Rules to validate the contested decision of 4 July 2013. On the one hand, the decision of 4 July 2013 is the result of an incorrect application of the PEAM Rules, repealed in 2009. On the other, the General Court, which initially referred to those PEAM Rules, then abandoned all reference to them in the course of the proceedings, putting forward as the sole legal basis the Financial Regulation of the European Union published in 2012.

Thirdly, the appellant complains that the General Court erred in law by making him alone bear the burden of proof.

Fourthly, the General Court committed a gross breach of the principle of impartial treatment required of all authorities of the European Union in the exercise of their tasks. The General Court failed entirely to take account of the political functions previously exercised by the Secretary-General of the European Parliament, the author of the contested decision.

Finally, the appellant complains that the General Court erred in law by accepting that the decision of 4 July 2013 rules on sums the recovery of which is in any event time-barred. The appellant thus submits that the failure by the General Court to have regard to the rules of limitation led to an infringement of the principle of non-retroactivity of Community acts, the principle of legitimate expectations and an infringement of the reasonable time principle.

---